{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:59:23Z","timestamp":1786993163364,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jpba.2015.02.045","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T19:31:45Z","timestamp":1425151905000},"page":"164-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Therapeutic drug monitoring of carbamazepine and its metabolite in children from dried blood spots using liquid chromatography and tandem mass spectrometry"],"prefix":"10.1016","volume":"109","author":[{"given":"Engy","family":"Shokry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Villanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Malvagia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Funghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ombrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Della Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"la Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2015.02.045_bib0165","series-title":"A Textbook of Epilepsy","first-page":"495","article-title":"Clinical pharmacology and medical treatment","author":"Richens","year":"1993"},{"key":"10.1016\/j.jpba.2015.02.045_bib0170","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(06)68182-8","article-title":"Epilepsy in children","volume":"367","author":"Guerrini","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2015.02.045_bib0175","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs","volume":"334","author":"Brodie","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2015.02.045_bib0180","first-page":"1109","article-title":"Carbamazepine dosing for pediatric seizure disorders: the highs and lows","volume":"25","author":"Gilman","year":"1991","journal-title":"D.I.C.P."},{"key":"10.1016\/j.jpba.2015.02.045_bib0185","first-page":"25","article-title":"Anticonvulsants in affective disorders","volume":"26","author":"Small","year":"1990","journal-title":"Psycopharmacol. Bull."},{"key":"10.1016\/j.jpba.2015.02.045_bib0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1192\/bjp.161.2.167","article-title":"Drug treatment of personality disorder","volume":"161","author":"Stein","year":"1992","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpba.2015.02.045_bib0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1212\/WNL.55.7.915","article-title":"Pharmacological treatment of pain in polyneuropathy","volume":"55","author":"Sindrup","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jpba.2015.02.045_bib0200","first-page":"80","article-title":"Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy","volume":"64","author":"Krasniqi","year":"2010","journal-title":"Med. Arch."},{"key":"10.1016\/j.jpba.2015.02.045_bib0205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2710.2006.00717.x","article-title":"Population pharmacokinetic modeling of carbamazepine in epileptic elderly patients: implications for dosage","volume":"31","author":"Bondareva","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2015.02.045_bib0210","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical pharmacokinetics of carbamazepine","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2015.02.045_bib0215","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007691-199812000-00012","article-title":"Carbamazepine-10,11-epoxide in therapeutic drug monitoring","volume":"20","author":"Potter","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2015.02.045_bib0220","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","article-title":"What is the right dose for children?","volume":"70","author":"Cella","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2015.02.045_bib0225","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/adc.2009.177592","article-title":"Facilitating pharmacokinetic studies in children: a new use of dried blood spots","volume":"95","author":"Patel","year":"2010","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.jpba.2015.02.045_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajhb.22463","article-title":"Development and validation of assay protocols for use with dried blood spot samples","volume":"16","author":"McDade","year":"2014","journal-title":"Am. J. Hum. Biol."},{"key":"10.1016\/j.jpba.2015.02.045_bib0235","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried blood spot methods in therapeutic drug monitoring methods: methods, assays and pitfalls","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2015.02.045_bib0240","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1167.2011.02978.x","article-title":"Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia","volume":"52","author":"Filippi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpba.2015.02.045_bib0245","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000350392","article-title":"A pharmacokinetic study and correlation with clinical response of rufinamide in infants with epileptic encephalopathies","volume":"91","author":"la Marca","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.jpba.2015.02.045_bib0250","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.clinbiochem.2008.02.017","article-title":"A decade of HPLC\u2013MS\/MS in clinical laboratory: goals for further developments","volume":"41","author":"Vogeser","year":"2008","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2015.02.045_bib0255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchromb.2013.02.005","article-title":"A simple bioanalytical method for the quantification of antiepileptic drugs in dried blood spots","volume":"923\u2013924","author":"Mohamed Shah","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2015.02.045_bib0260","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jcph.170","article-title":"Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spots and plasma concentrations from people with epilepsy: the clinical implication","volume":"54","author":"Kong","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2015.02.045_bib0265","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/bmc.363","article-title":"Simple and rapid micellar electrokinetic capillary chromatographic method for simultaneous determination of four antiepileptics in human serum","volume":"18","author":"Casas","year":"2004","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2015.02.045_bib0270","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1081\/JLC-100101775","article-title":"An HPLC assay for carbamazepine phase I metabolites and their glucuronides in urine","volume":"22","author":"Reith","year":"1999","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2015.02.045_bib0275","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/10826079408013179","article-title":"Simultaneous HPLC analysis of carbamazepine and carbamazepine epoxide in human brain microdialysate","volume":"17","author":"Scheyer","year":"1994","journal-title":"J. Liq. Chromatogr."},{"key":"10.1016\/j.jpba.2015.02.045_bib0280","series-title":"US FDA Guidance for Industry\/Bioanalytical Method Validation","author":"United States Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.jpba.2015.02.045_bib0285","series-title":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: Validation of analytical procedures: text and methodology Q2(R1)","year":"2005"},{"key":"10.1016\/j.jpba.2015.02.045_bib0290","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpba.2015.02.045_bib0295","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","article-title":"Therapeutic drug monitoring of old and newer anti-epileptic drugs","volume":"42","author":"Neels","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2015.02.045_bib0300","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2125.2000.00125.x","article-title":"Drug trials in children: problems and the way forward","volume":"49","author":"Conroy","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2015.02.045_bib0305","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology \u2013 drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2015.02.045_bib0310","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.4155\/bio.10.103","article-title":"The effect of hematocrit on assay bias when DBS sampler fort the quantitative bioanalysis of drugs","volume":"2","author":"Denniff","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2015.02.045_bib0315","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC\u2013MS\/MS for quantitative analysis of small molecules","volume":"24","author":"Li","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2015.02.045_bib0320","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpba.2010.07.015","article-title":"Rapid assay of rufinamide in dried blood spots by a new liquid chromatography\u2013tandem mass spectrometric method","volume":"54","author":"la Marca","year":"2011","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515001508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515001508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T15:26:45Z","timestamp":1537802805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708515001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":32,"alternative-id":["S0731708515001508"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2015.02.045","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of carbamazepine and its metabolite in children from dried blood spots using liquid chromatography and tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2015.02.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}